This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Paradiso, A. Articles by De Lena, M. Search for Related Content PubMed PubMed Citation Articles by Paradiso, A. Articles by De Lena, M.

Randomized Clinical Trial of Adjuvant Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy for Patients With Fast-Proliferating, Node-Negative Breast Cancer

From the Clinical Experimental Oncology Laboratory, Senology Unit, Histopathology Service, and Medical Oncology Unit, National Oncology Institute, Bari, Italy.

Address reprint requests to Angelo Paradiso, MD, Clinical Experimental Oncology Laboratory, National Oncology Institute, Via Amendola, 209, 70126 Bari, Italy; email: anpara{at}tin.it

PURPOSE: The prospective applicability of new biologic tumor information to personalize adjuvant treatment of women with operable breast cancer remains to be demonstrated. The aim of the present study was to investigate whether patients with fast-proliferating, node-negative breast cancer could benefit from adjuvant chemotherapy with fluorouracil, epirubicin, and cyclophosphamide (FEC).

PATIENTS AND METHODS: Beginning in November 1989, we analyzed the proliferative activity of primary tumors in a consecutive series of women with node-negative breast cancer to identify subgroups of patients with a worse prognosis and who were therefore suitable candidates for adjuvant systemic therapy. Proliferative activity was determined by means of the [³H]-thymidine incorporation assay using an autoradiographic technique. Women with fast-proliferating breast cancer ([³H]-thymidine labeling index, > 2.3%) were randomized to receive either six cycles of adjuvant FEC or no adjuvant therapy until disease progression.

RESULTS: One-hundred twenty-five and 123 patients treated with radical surgery for pT1 to T2, N0, M0 breast cancer were randomized to the FEC and control arms, respectively. After a median follow-up of 70 months, 27 events (21.6%) were observed in the FEC arm and 39 (32.2%) in the control arm, with a significantly lower number of locoregional relapses in the FEC group. Five-year disease-free survival (DFS) was 81% in the FEC group and 69% in the control group (P < .02 by log-rank test). Cox multivariate analysis described the impact of adjuvant therapy with FEC on DFS as independent of the patients’ main clinical-pathologic characteristics.

CONCLUSION: FEC adjuvant polychemotherapy seems able to significantly improve the clinical outcome of patients with fast-proliferating, node-negative breast cancer.

This article has been cited by other articles:

				M. Colozza, E. Azambuja, F. Cardoso, C. Sotiriou, D. Larsimont, and M. J. Piccart Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann. Onc., November 1, 2005; 16(11): 1723 - 1739. [Abstract] [Full Text] [PDF]

				P J van Diest, E van der Wall, and J P A Baak Prognostic value of proliferation in invasive breast cancer: a review J. Clin. Pathol., July 1, 2004; 57(7): 675 - 681. [Abstract] [Full Text] [PDF]

				A. Volpi, O. Nanni, F. De Paola, A. M. Granato, A. Mangia, F. Monti, F. Schittulli, M. De Lena, E. Scarpi, P. Rosetti, et al. HER-2 Expression and Cell Proliferation: Prognostic Markers in Patients With Node-Negative Breast Cancer J. Clin. Oncol., July 15, 2003; 21(14): 2708 - 2712. [Abstract] [Full Text] [PDF]

				A.-S. Schrohl, M. Holten-Andersen, F. Sweep, M. Schmitt, N. Harbeck, J. Foekens, and N. Brunner Tumor Markers: From Laboratory To Clinical Utility Mol. Cell. Proteomics, June 1, 2003; 2(6): 378 - 387. [Full Text] [PDF]